Can a Drug Addict Donate Organs After Death?

People who used drugs can and routinely do donate organs after death. No blanket rule in the United States or most other countries disqualifies a potential donor based on a history of substance use. Instead, each donor is evaluated individually, organ by organ, through medical testing and clinical judgment. The rise in overdose deaths has actually made this one of the fastest-growing segments of the deceased-donor pool, and the transplant outcomes from these donors have been, on the whole, remarkably good.

How Drug Overdose Deaths Reshaped the Donor Pool

Overdose deaths accounted for less than one percent of all deceased organ donors in the United States in 2000. By 2017, that figure had climbed to about 14%, representing more than 1,400 donors. In some of the hardest-hit states, drug intoxication became the leading circumstance of death among organ donors. Between 2010 and 2016 alone, the number of donors who died from drug overdose rose roughly 277%, even as the overall donor pool grew by about 26%.¹ That trend continued: between 2016 and 2022, the vast majority of U.S. counties saw overdose-related deaths increase further, and donors who died from overdose rose another 42%.²

Crucially, these donors tend to be younger and healthier in many respects than the average deceased donor. They are less likely to have diabetes or hypertension, and their kidneys often score favorably on standardized quality indices.¹ In a system where more than 100,000 people sit on transplant waiting lists, turning away organs from donors with substance use histories would be a devastating loss.

Do Organs From These Donors Actually Work Well?

This is the question that matters most to transplant recipients, and the evidence is encouraging. A large U.S. registry study comparing overdose-death donors to trauma-death donors and medical-death donors found that standardized five-year patient survival was similar across all three groups, with differences ranging from about three percentage points lower to four percentage points higher depending on the organ type. Five-year graft survival for kidneys and lungs was also comparable, while liver graft survival from overdose-death donors was only marginally lower and heart graft survival was marginally higher.³

The kidney data is particularly striking. A Canadian study found that recipients of kidneys from drug-toxicity-death donors had a five-year graft survival rate of 97%, compared with 83% for recipients of kidneys from donors who died of other causes. Recipients of drug-toxicity donor kidneys had a significantly lower risk of graft loss overall, driven largely by the especially strong results from younger donors.⁴ Again, the youth and relative health of these donors likely explains much of the advantage.

For livers, a study examining brain-dead donors found that drug-intoxication cause of death was associated with better one-year graft survival compared to donors who died from trauma or stroke.⁵ An earlier study of liver transplants from chemical-overdose donors reported an 86% one-year graft survival rate and concluded that cautious use of these grafts is a worthwhile method of expanding the donor supply.⁶

Hearts From Donors Who Used Stimulants

Heart donation from people who used cocaine or methamphetamine has historically been one of the most contentious areas in transplant medicine. The concern is straightforward: cocaine can cause coronary artery disease, coronary spasm, and heart attacks; methamphetamine has been linked to cardiotoxicity.⁷ Many transplant programs once refused these hearts outright.

But the data has been more reassuring than the fear. A study examining heart transplant outcomes from drug-intoxicated donors found that survival at one, three, and five years was essentially the same as for hearts from non-drug-intoxicated donors, with one-year survival around 90% in both groups. Rates of acute rejection in the first year were also similar. Combinations of drugs identified through toxicology testing were not associated with differences in survival.⁸ Another study confirmed that toxicological findings in donors did not predict worse post-transplant mortality.⁹

There is a notable exception that deserves attention. A 2025 study looking specifically at pediatric heart transplant recipients found that while short-term outcomes were fine, long-term graft loss was roughly twice as likely in children who received a heart from a donor with a cocaine history compared to controls.¹⁰ This is one of the first studies to flag a meaningful long-term signal in this population, and it suggests that the reassuring picture may not apply uniformly across all age groups and organ types. Pediatric transplantation involves different physiology and much longer expected graft lifespans, so the cumulative effect of any subclinical damage could become significant over decades.

Lungs and the Smoking-and-Crack-Cocaine Question

Lungs are the organ most directly exposed to inhaled substances, which makes them a special case. A study of lung transplant outcomes from donors with a history of substance use found that heavy smoking was associated with increased risk of death or retransplant and higher rates of primary graft dysfunction. Donor crack cocaine use, though studied in a small group, was also associated with worse survival.¹¹ Lungs are already the most frequently declined organ due to injury sensitivity, so the added scrutiny for substance-exposed lungs makes clinical sense. Transplant teams evaluate each pair of lungs through imaging, bronchoscopy, and gas-exchange testing before deciding whether to proceed.

The Hepatitis C Problem That Became an Opportunity

One of the most legitimate concerns about donors who used injection drugs has been the risk of transmitting hepatitis C virus. Among donors who died from drug overdose between 2010 and 2016, about 19% had HCV infection.¹ Discarded overdose-death heart allografts were far more likely to be hepatitis C positive than those that were used.¹² For years, HCV-positive status was close to a death sentence for donated organs.

That changed dramatically with the arrival of direct-acting antiviral drugs. These medications can cure hepatitis C in nearly everyone who takes them, and transplant centers have begun using HCV-positive organs in HCV-negative recipients with a plan to treat the virus after transplant. In multiple studies, this approach has worked remarkably well. One trial of kidney transplants from HCV-positive deceased donors to HCV-negative recipients treated with direct-acting antivirals found that all ten patients had no detectable virus twelve weeks after finishing treatment.¹³ Research on even shorter antiviral courses has shown promise: a seven-day prophylaxis regimen reduced HCV transmission to about 4% of recipients, and the few who did develop infection were cured with full-course treatment afterward.¹⁴

The practical effect has been to open a significant new pool of organs. Hearts, livers, and kidneys from HCV-positive donors that would have been discarded a decade ago are now being transplanted successfully, with recipients cured of HCV before it can cause liver damage.

Hepatitis B and HIV Donors

Hepatitis B presents a different set of challenges. Organs from donors who are hepatitis B core antibody positive can transmit HBV to the recipient, but antiviral prophylaxis can prevent this. Recipients of liver grafts from these donors are typically placed on antiviral therapy starting immediately after transplant and monitored for HBV DNA at regular intervals.¹⁵ ¹⁶

HIV-positive donors represent perhaps the most dramatic policy shift. The HIV Organ Policy Equity (HOPE) Act now permits transplantation of organs from HIV-positive donors to HIV-positive recipients in the United States.¹⁷ Early results have been promising. Kidney transplantation from donors with HIV to recipients with HIV appears comparable in safety to transplantation from HIV-negative donors to HIV-positive recipients.¹⁸ For liver transplant candidates willing to accept HOPE donor livers, the median time to transplant dropped to about 2.3 months, compared with over a year for candidates not willing to accept these organs, and the overall transplant rate was roughly threefold higher.¹⁹ For people with HIV who need a transplant, this has been genuinely life-changing.

What Screening Actually Looks Like

Every potential deceased donor in the United States goes through an evaluation process regardless of their medical or social history. No one is accepted or rejected based on a single factor. The organ procurement organization collects a thorough medical and social history, performs blood work, screens for infectious diseases using nucleic acid testing, and assesses each organ’s function individually.

Nucleic acid tests can detect HIV, hepatitis B, and hepatitis C at very low viral levels, and the detection window has gotten shorter as the technology has improved. Updated models show significantly shorter window periods for HBV and HCV detection, though the window for HIV sits at the lower range of previously published estimates.²⁰ This means that while the risk of undetected infection has shrunk considerably, it has not reached zero, particularly for someone who acquired an infection very recently before death. That residual risk is one reason donors with certain behavioral histories are labeled “increased risk” by the Public Health Service.

The “increased risk” label does not mean the organs are unusable. It means recipients must give specific informed consent before accepting them. The actual risk of an undetected infection in the modern testing era is extremely small, generally estimated at less than one in several hundred in worst-case scenarios.

The Informed Consent Dilemma

Here is where the system creates an unintended problem. Transplant centers are required to inform potential recipients when organs come from a donor flagged as increased risk, but the way that information is delivered can scare patients away from organs that would likely save their lives. The Organ Procurement and Transplantation Network mandates specific informed consent but historically has not provided detailed guidelines on what exactly should be disclosed or how to frame it.²¹

Research has shown that patients unwilling to accept organs from increased-risk donors experienced lower transplant rates and higher risk of dying on the waiting list, even though the worst-case risk of viral transmission was estimated at roughly one in 300 to one in 1,000. The use of terms like “HIV” as part of the disclosure process may function as a trigger that causes disproportionate refusal.²² In other words, the consent process designed to protect patients may paradoxically harm some of them by steering them away from good organs.

The Public Health Service revised its guidelines in recent years to narrow the increased-risk criteria and encourage more nuanced conversations, but the stigma effect persists. If you or a loved one is on a transplant waiting list, it is worth having a frank conversation with your transplant team in advance about which types of donor offers you would and would not want to consider, so that decisions are not being made in the heat of the moment at 3 a.m. when an organ becomes available.

When the Medical Examiner Gets Involved

Drug-related deaths frequently fall under the jurisdiction of a medical examiner or coroner, which introduces a logistical complication. These officials have legal authority over the body and must determine cause and manner of death. In some cases, the medical examiner denies organ recovery because they need the body preserved for forensic investigation. A study in the early 1990s found that roughly 7 to 11% of medical examiner cases were denied organ recovery, and the trend was increasing at that time.²³

Collaboration between organ procurement organizations and medical examiners has improved considerably since then. Modern protocols allow procurement teams to photograph organs, collect tissue samples for the medical examiner, and document injuries in ways that preserve forensic evidence while still allowing donation to proceed. But the tension between forensic needs and transplant urgency has not fully disappeared, and the outcome can vary by jurisdiction.²⁴ In a drug death, time is critical: organs need to be recovered quickly, but the cause-of-death investigation may require exactly the kind of careful, unhurried examination that donation complicates.

When Kidney Injury From an Overdose Does Not Doom the Kidney

One concern specific to overdose deaths is that the dying process itself can injure organs. Opioid overdoses, for instance, sometimes involve a period of low blood pressure or oxygen deprivation before death, which can damage the kidneys. When a donor has acute kidney injury at the time of death, as reflected by elevated creatinine levels, transplant teams face a judgment call: is this kidney too damaged, or will it recover once transplanted into a healthy recipient?

A large meta-analysis found that kidneys from donors with acute kidney injury were more likely to have delayed graft function, meaning the recipient needed temporary dialysis after transplant, but one-year and five-year graft survival were no different from kidneys without acute kidney injury. Even kidneys from donors with the most severe stage of acute injury showed comparable one-year function.²⁵ The key distinction appears to be whether the kidney injury was still worsening at the time of organ recovery or had started to recover. Kidneys from donors whose acute injury was improving were associated with outcomes similar to non-injured kidneys, while persistent severe injury carried a higher risk of graft failure and recipient death.²⁶

The practical implication is that an overdose donor whose kidneys took a hit during the dying process may still yield perfectly transplantable organs, particularly if the injury had begun to resolve before brain death was declared. Transplant teams use serial lab values to track the trend and make a judgment call rather than relying on a single snapshot.

The Stigma Gap Between Public Perception and Medical Reality

Despite the strong clinical evidence, public attitudes toward organs from donors with substance use disorders remain complicated. Research measuring attitudes toward organ donation found that respondents were presented with hypothetical donors who had various health histories, including people in treatment for a substance use disorder, and measured willingness to accept organs from each. Substance use disorder consistently drew more negative attitudes than many other health conditions.²⁷

That stigma also works from the donor-family side. Families of people who died from overdoses sometimes assume their loved one’s organs would be rejected, and some do not raise the possibility of donation with hospital staff. Organ procurement organizations have been working to change this perception through public education campaigns, but the mismatch between what the evidence shows and what the public believes remains wide. If you are ever in the position of making a donation decision for a family member who died from a drug overdose, the clinical answer is clear: their organs could save multiple lives, and the transplant system has the tools to evaluate and use them safely.

Which Drugs Matter More Than Others

Not all substances affect all organs the same way, and transplant teams weigh the specifics rather than applying a blanket policy. Opioids, the most common cause of overdose death among donors, do not typically damage solid organs directly. The danger lies in the dying process: respiratory depression leading to low oxygen, low blood pressure, and potential aspiration. If those secondary insults are managed or limited, the organs themselves are often in excellent condition, which is why opioid-overdose donors have such strong outcome data.

Cocaine and methamphetamine are more directly toxic to the heart, as discussed earlier, but even here the data generally supports careful use. Alcohol, particularly chronic heavy use, can damage the liver, but a history of drinking does not automatically render a liver untransplantable; biopsy findings guide the decision. Marijuana has not been shown to affect organ transplant outcomes in any meaningful way. Intravenous drug use of any kind raises the infection risk, which is managed through the screening and testing protocols already described.

The overarching principle is that the transplant system evaluates the organ, not the person. A heart that looks healthy on echocardiogram, performs well hemodynamically, and comes from a young donor is a good heart, regardless of what substances were found in the donor’s bloodstream. A liver with minimal fibrosis on biopsy is a usable liver. The focus is on function, not biography.

1
PubMed. Effect of the Opioid Crisis on the Donor Pool for Kidney Transplantation: An Analysis of National Kidney Deceased Donor Trends from 2010-2016
2
PubMed. Effect of the opioid crisis on the liver transplantation donor pool: A national analysis
3
PubMed Central. The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States: A National Registry Study
4
PubMed Central. Observational Study Examining Kidney Transplantation Outcomes Following Donation From Individuals That Died of Drug Toxicity in British Columbia, Canada
5
PubMed. Implications of drug intoxication on donor utilization and outcomes in liver transplantation
6
Transplantation. The impact of donor chemical overdose on the outcome of liver transplantation
7
The Journal of Heart and Lung Transplantation. Is There a Risk of Cocaine and Methamphetamine Use in Heart Donors?
8
American Journal of Transplantation. Changing demographics of heart donors: The impact of donor drug intoxication on posttransplant survival
9
PubMed Central. Intoxicated Donors and Heart Transplant Outcomes: Long-Term Safety
10
PubMed Central. Donor History of Drug Use and Graft Survival in Pediatric Heart Transplant Recipients
11
PubMed Central. Lung Transplantation From Donors With a History of Substance Use
12
PubMed. Impact of the Opioid Epidemic on Heart Transplantation: Donor Characteristics and Organ Discard
13
PubMed Central. Transplantation of Organs from Hepatitis C Virus-Positive Donors under Direct-Acting Antiviral Regimens
14
American Journal of Transplantation. Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients
15
PubMed Central. Hepatitis B Virus Infection and Organ Transplantation
16
Journal of Liver Transplantation. The use of Hepatitis B Core Antibody and nucleic acid testing positive organs in safe and effective in Hepatitis B naïve liver transplant recipients
17
PubMed Central. Realizing HOPE: The Ethics of Organ Transplantation From HIV-Positive Donors
18
PubMed Central. Infections After Kidney Transplantation From Donors With HIV to Recipients With HIV
19
PubMed Central. Increased rate of deceased donor liver transplantation for candidates willing to receive organs from donors with human immunodeficiency virus
20
PubMed. Revised nucleic acid test window periods: Applications and limitations in organ donation practice
21
American Journal of Transplantation. The Challenge of Informed Consent for Increased Risk Living Donation and Transplantation
22
PubMed Central. Consent to organ offers from public health service “Increased Risk” donors decreases time to transplant and waitlist mortality
23
PubMed. Impact of medical examiner/coroner practices on organ recovery in the United States
24
PubMed. The role of the medical examiner/coroner in organ and tissue procurement for transplantation
25
PubMed Central. Impact of deceased donor acute kidney injury (AKI) on renal transplant outcomes
26
PubMed Central. Impact of acute kidney injury and renal recovery status in deceased donor to kidney transplant outcome: results from the Thai national transplant registry
27
PubMed Central. Attitudes Toward Organ Donation for Persons Who Have a Substance Use Disorder Relative to Other Health Conditions